Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 2/20 | 0.57 |
| ▸ | PPARA | Q07869 | 2/20 | 0.57 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 4/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | APP | P05067 | 2/20 | 0.54 |
| ▸ | OSBP | P22059 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 3/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Geroquinol SCHEMBL29929565 | 1.00 | ALOX5 (0.57) | ALOX5ALOX15PPARGPPARACTSK | |
| Geroquinol SCHEMBL557013 | 1.00 | ALOX5 (0.57) | ALOX5ALOX15PPARGPPARACTSK | |
| SCHEMBL2943955 | 0.98 | ALOX5 (0.59) | ALOX5ALOX15PPARGPPARACTSK | |
| SCHEMBL31536036 | 0.98 | ALOX5 (0.59) | ALOX5ALOX15PPARGPPARACTSK | |
| Geranylgeranylhydroquinone SCHEMBL8025990 | 0.98 | ALOX5 (0.59) | ALOX5ALOX15PPARGPPARACTSK | |
| SCHEMBL8017471 | 0.98 | ALOX5 (0.59) | ALOX5ALOX15PPARGPPARACTSK | |
| SCHEMBL31405831 | 0.88 | ALOX5 (0.58) | ALOX5ALOX15PPARGPPARACTSK | |
| SCHEMBL7075584 | 0.88 | ALOX5 (0.58) | ALOX5ALOX15PPARGPPARACTSK | |
| SCHEMBL23896921 | 0.88 | MAOB (0.57) | PPARGPPARACTSKBACE1PTPN1 | |
| SCHEMBL8650303 | 0.87 | ALOX5 (0.57) | ALOX5ALOX15PPARGPPARACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118853527-A | Fungus fermentation liquor and application thereof | 徐州医科大学 | 2024-10-29 | — | — | CN | claimed |
| CN-118795124-A | Biomarker for predicting aging and application thereof | 深圳华大生命科学研究院 | 2024-10-18 | — | — | CN | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| CN-112322592-B | CYP76B100 protein involved in alkannin biosynthesis, coding gene thereof and application thereof | 中国科学院天津工业生物技术研究所 | 2021-12-28 | — | — | CN | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021042001-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | Natural Extraction Systems, LLC (US) | 2021-03-04 | — | — | WO | claimed |
| CN-112322592-A | CYP76B100 protein involved in alkannin biosynthesis, coding gene thereof and application thereof | 中国科学院天津工业生物技术研究所 | 2021-02-05 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-104244968-A | PH20 polypeptide variants, formulations, and uses thereof | HALOZYME INC | 2014-12-24 | — | — | CN | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | NATURAL EXTRACTION SYS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| WO-1997014421-A1 | NAMENAMICIN, AN ENEDIYNE ANTITUMOR ANTIBIOTIC FROM THE MARINE ASCIDIAN POLYSYNCRATON LITHOSTROTUM | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | ALOX5 264/4885ALOX15 359/4885PPARG 319/4885 |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | SCO2, CNR2, CNR1 | ALOX5 307/4885ALOX15 233/4885PPARG 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.